breakthrough Therapy

News

Enhertu gets breakthrough tag in HER2-low breast cancer

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing the drug extended survival in patients with HER2-low metastatic

News

FDA gives Daiichi Sankyo's HER3 drug a breakthrough tag

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer.

News

Enhertu nabs speedy FDA review for earlier use in breast can...

Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca and Daiichi Sankyo have claimed FDA breakthrough status for the drug that should

News